Evaluation Study of the Intestinal Microbiota and Quality of Life in Patients Suffering From IBS Treated With Bifidice
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Irritable bowel syndrome is the most common functional gastrointestinal disease and is
characterized by high prevalence and chronic course.The pathology has a strong impact on the
quality of life of affected patients and on health and social costs, these related to reduced
productivity.The scarce efficacy and heavy side effects of traditional therapies lead these
patients to often resort to alternative or complementary therapies. From the evaluation of
the evidence of various probiotic preparations and food supplements, the investigators have
used a commercial preparation characterized by the presence of bifidobacteria which have
demonstrated some efficacy in thinking of improving the quality of life of these patients to
evaluate quality of life, ability productivity and trend of some indices of disease severity
in a small number of patients. These preliminary data could represent a starting point for
more in-depth evaluations, also with placebo-controlled studies.